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BACKGROUND: Increasing free radicals and oxidative stress due to chronic hyperglycemia in type-2 diabetes mellitus (DM) promotes the 
activity of endogenic antioxidative genes. Nuclear factor 
erythroid 2-related factor 2 (Nrf2) expression and activity 
are important to regulate the production of endogenic 
antioxidative enzymes.
CONTENT: Normally, Nrf2 is bound by protein Kelchlike 
ECH-associated protein-1 (Keap1) in the cytosol. 
Stimulation from oxidative stress causes the release of Nrf2 
from Keap1. When activated, Nrf2 enters the nucleus and 
activates the antioxidant response element (ARE). This will 
further increase the production of antioxidative enzymes, 
such as catalase, nitrite oxydase and heme oxygenase-1. The 
discovery of oxidative stress, as the cause of complications 
in DM, gives rise to the idea of  developing a treatment 
which can increase the expression and  activity  of  Nrf2, 
one  of  which  is  a  flavonoid antioxidant. 
SUMMARY: Currently, nuclear factor erythroid 2-related 
factor 2 is an important target in the therapy of DM.
KEYWORDS: Nrf2, type-2 diabetes mellitus, endogenic 
antioxidative enzymes, oxidative stress, antioxidants
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Abstract
Introduction
Diabetes mellitus (DM) is a chronic metabolic disorder 
which causes many complications. In 2005, the disease was 
reportedly affecting 135 million people. This accounts for 
3% of the total world population, including poor residents 
in rural and urban areas.(1) The number of people in the 
world suffering from DM is predicted to reach 522 million 
in 2030.(2) According to data from the National Institutes 
of Health (NIH), around 90-95% cases of DM are type-2 
DM.(3) In 2000, WHO reported that around 8.4 million 
people in Indonesia were affected by the disease. This 
number is projected to reach 21.3 million in 2030.(4) 
This large number of DM cases, as well as its constant 
increase, imposes a major burden on the country, especially 
due to the need to fund the health expenses required for 
treatment. Furthermore, DM also reduces the quality of life 
and productivity of its patients. Therefore, management 
of DM through using natural and affordable materials, in 
addition to current  antidiabetic  drugs, should continue to 
be developed.
 Complications relating to DM are the leading cause of 
death in DM patients. Chronic hyperglycemia is the initial 
cause of microvascular complications, such as retinopathy, 
neuropathy and nephropathy, as well as macrovascular 
complications, especially cardiomyopathy. Hyperglycemia 
stimulates the production of pathological oxidants, increases 
peroxidation of lipid and disrupts cellular signaling 
pathways, such as phospholipid or kinase, increasing the 
oxidative stress of cells.(5) The increase of reactive oxygen 
species (ROS) has been known as the main cause of cellular 
death in DM patients. Chronic hyperglycemia promotes the 
production of ROS and peroxidation of lipid, increasing the 
oxidative stress that may damage the muscle cells.(6)
 Efforts to prevent complications of DM include 
reducing the excessive production of ROS. This can be 
achieved through a scavenging mechanism by the endogenic 
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antioxidants, such as superoxide dismutase (SOD). 
Production of endogenic antioxidants is regulated mainly by 
the nuclear factor erythroid 2-related factor 2 (Nrf2) system. 
An activated Nrf2 will induce the antioxidant response 
element (ARE). Furthermore, the ARE will stimulate 
transcription of genes that code endogenic antioxidative 
enzymes, such as SOD, heme oxygenase (HO-1), catalase, 
and glutathione S-transferase (GST). Normally, Nrf2 
forms a complex with Kelchlike ECH-associated protein-1 
(Keap1) in the cytoplasm. Cellular injury due to oxidative 
stress promotes the release of Nrf2 from Keap1, then free 
Nrf2 will be activated and enter the nucleus to stimulate the 
genes producing endogenic antioxidants.(7)
 Increasing Nrf2 activity in the presence of ROS, or 
the administration of antioxidants, has been widely proven 
to reduce oxidative stress. Previous studies shows that Nrf2 
plays an important role in the in vitro protection of cardiac 
muscle cells from injuries and death caused by oxidative 
stress induced by hyperglycemia.(8) In another study, rats 
which have their Nrf2 removed show more severe cardiac 
muscle injuries than those whose Nrf2 are intact after 
induction with streptozotocin (STZ).(9)
 With the discovery of the important effect of Nrf2 
in reducing oxidative stress, a DM therapy targeting this 
system needs to be developed. Using Nrf2 as a therapeutic 
target has many advantages, such as protecting cells from 
damage, increasing insulin sensitivity, and preventing 
micro and macrovascular complications. The main purpose 
of using Nrf2 as a therapeutic target is to adopt its ability 
to reduce ROS,  as well as its  potential  to  decrease 
peroxidation of lipid  and  oxidative  stress  in  order  to 
prevent  complications.(10)
Nrf2
Nrf2 is a transcription activator which will be activated when 
it binds to the ARE in the promoter region of the target gene. 
Nrf2 has a heterodimer formation, forming a complex with 
Keap1 through an interaction with leucine-zipper group. It is 
expressed in almost of the cells, especially in muscle tissue, 
including cardiac muscle, skeletal muscle, the kidneys, the 
lungs, and the liver. Nrf2 is located in chromosome 2q31. 
Nrf2 consists of 165,103 bases in humans, whereas in rats it 
ranges in size from 75.68 to 75.7 Mb.(11)
Activities of Nrf2
Normally, Nrf2 can be found binding to the Keap1 in the 
cytoplasm. This binding will promote the ubiquitination of 
Nrf2 and its degradation by proteasome. The presence of 
oxidative stress will trigger a residual change of lysine in 
Keap1 protein, releasing Nrf2 from its bond with Keap1. 
Free Nrf2 will enter the nucleus to activate ARE/electrophile 
response element (EpRE). A signal will be formed afterward 
through three pathways: the mitogen-activated protein 
kinase (MAPK) cascade, the phosphatidylinositol 3-kinase 
(PI3K), and the protein kinase C (PKC).(12,13) PI3K is an 
important component in insulin-signalling pathways and 
can be activated by phenol-group antioxidants. 
 The movement of Nrf2 into the nucleus is also 
mediated by PKC. Other protein kinases, such as Protein 
kinase RNA-like endoplasmic reticulum kinase (PERK) and 
Protein kinase B/Akt, are also able to phosphorylate and 
activate Nrf2.(14)
Roles of Nrf2
The Nrf2 system is expressed in many cells and biological 
systems. Nrf2 controls several enzymes production, 
including antioxidative enzymes. Thus it plays an important 
role  in  cellular  defense  mechanisms  against  oxidative 
stress.  Nrf2  is  also  involved in  lipid  metabolism  and 
insulin  action.(15)  Nrf2  helps regulate  insulin  activity 
and  maintain  metabolic  processes in body. Previous 
studies show that activation of Nrf2 is affected by insulin-
signalling pathways. Moreover, Nrf2 activity will decrease 
in the presence of insulin resistance.(16)
 Another study also mentions the importance of 
Nrf2 in improving the performance of insulin-signalling 
pathways, especially in the presence of insulin resistance. 
Circulating ROS may disrupt a normal insulin signalling 
pathway by causing an imbalance between reduction and 
oxidation, inhibiting insulin action in the process.(17) Nrf2 
maintains the balance between reductive and oxidative 
reactions by reducing lipid synthesis. Thus it plays a role as 
an anti-obesity agent. Nrf2 activity in adipose cells inhibits 
adipogenesis and differentiation of immature fat cells. 
Maturation and differentiation of fat increases in reduction-
oxidation imbalances.(18) 
 It   is   hypothesized   that   Nrf2   reduces   the 
differentiation  of  fat  cells  by  maintaining  the  balance 
of reductive-oxidative  reactions,  as  well  as by decreasing 
the genes  that promote adipogenesis. This mechanism is 
similar to the action of peroxisome proliferator-activated 
receptors-γ (PPAR-γ).(7)  Previous  study  shows  that 
administration of substances  which  increase  the  activity 
of  Nrf2  in  rats  fed  with  a  high-fat  diet  can  prevent 
weight gain, lower the  mass  of  adipose  tissue,  and  prevent 
a  fatty  liver.(19)
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Nrf2 as A Target in The Therapy of DM
Activation of Nrf2 by AntioxidantsThe ARE The ARE is a specific cis-acting codon formation which 
plays an important role in the activation mechanism 
of chemoprotective genes. The ARE codon formation 
is identified in promoter genes which are involved in 
chemoprotective systems, including antioxidative genes. 
One of the factors required in the activation of ARE is 
Nrf2. Activated Nrf2 entering the nucleus will bind to 
the ARE and form a complex with a musculoaponeurotic 
fibrosarcoma (Maf)G or MafK protein family which 
can increase ARE activity. Once activated, the ARE will 
increase the transcription of genes that code antioxidative 
genes, such as NADPH: quinone oxidoreductase-1, HO-1, 
and catalase.(20)
The role of Nrf2 in maintaining the homeostasis of glucose, 
lipid  and  protein  metabolism,  also  in  activity of 
antioxidants in the body, makes Nrf2 becomes an important 
target in the management of DM. Oxidative stress is 
known as the main cause of DM complications, making 
the modification of endogenic antioxidant activity, one of 
them through the role of Nrf2, an important objective in the 
therapy of DM.(21)
 Nowadays, more natural substances have been 
proven to have the ability to activate Nrf2 in DM therapy. 
These natural Nrf2-activating agents include resveratrol, 
curcumin, catechin, and quercetin. The Nrf2-activating 
agents work by promoting the depolarization of membrane 
potential in mitochondria that will activate Nrf2. Because 
these agents are electrophilic, they can modify the cysteine 
residual complex in Keap1 protein, breaking its bond with 
Nrf2.(22) The Nrf2 will then enter the nucleus and avoid the 
degradation process. Activated Nrf2 will activate the ARE 
and increase the production of endogenic antioxidative 
enzymes. The increase of Nrf2 activity will also improve 
insulin sensitivity. This is what underlies the importance of 
Nrf2 as a therapeutic target for DM in the future.(23)
 Another advantage of using Nrf2 as a therapeutic target 
for DM is its role in regulating lipid and glucose metabolism. 
Its role in regulating lipid metabolism prevents obesity in 
DM  patients,  whereas several oral antihyperglycemic drugs 
reportedly cause it, especially glibenclamide. Not only that, 
but Nrf2 also helps protect pancreatic β-cells and increases 
insulin production.(24) Administration of Nrf2-activating 
agents in DM therapy has been widely tested in vivo, but its 
administration to humans still needs further research.
The ability of flavonoid antioxidants to increase the activity 
of endogenic antioxidants is related to its role in increasing 
the release of Nrf2 from its bond with Keap1 into the 
nucleus, to activate ARE/EpRE. The ARE/EpRE complex 
can be found in many promoter genes involved in the 
cellular defense mechanism. Genes such as Nrf1, Nrf2 and 
Nrf3 have the capacity to activate the ARE/EpRE. The Nrf 
1 or 2 which binds to the ARE/EpRE will activate the genes 
of antioxidative enzymes which are important in regulating 
detoxification and the cellular defense mechanism.(22)
 The Nrf1 and Nrf2 can also form a heterodimer 
complex with target DNA with protein basic leucine zipper 
domain (bZIP), MafF, and MafK. Nrf2 can also form a 
heterodimer complex with target DNA with proto-oncogene 
proteins c-Jun, activating transcription factor 4 (ATF4), 
polyamine-modulated factor (PMF) and PPAR-γ which are 
also involved in the homeostasis of glucose and lipid.(25)Nrf2 and The Effect of Flavonoid Antioxidants on Nrf2 in Cardiac Muscles
A population study finds that 90% of cardiomyopathies 
are attributed  to  the  increase  of  oxidative stress in DM 
patients.(26) An in vitro observation of the increasing 
production of ROS in the presence of hyperglycemia shows 
an increase in apoptosis and mitochondrial injuries leading 
to infarction in cardiac muscles.(8) Mitochondrial injuries 
cause an imbalance in reductive-oxidative reactions, 
inhibition of electron transport in respiratory chain, and 
disorders in various signaling pathways.(27)
 Increasing ROS and oxidative stress in cardiac muscles 
promote cellular apoptosis and mitochondrial injuries by 
mitochondrial complex II inhibitor 3-nitropropionic acid. 
Mitochondrial injuries will reduce the sensitivity of cardiac 
muscles against β-adrenergic agonist that is essential for 
their contraction. Not only that, mitochondrial injuries will 
reduce their sensitivity toward protective enzymes, including 
the endogenic oxidative enzymes. The Nrf2 is important in 
preventing infarction in cardiac muscles by decreasing ROS 
and oxidative stress. A study using the cardiac muscles of 
rats shows a higher level of ROS in those without the Nrf2. 
A short-term, mild hyperglycemic induction in rats without 
the Nrf2 causes an increase in cardiac muscle cell apoptosis, 
compared to in those with the Nrf2.(8) Lower expression of 
Nrf2 in cardiac muscles also causes nitrosative damage and 
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phosphorylation of Extracellular signal-regulated kinases 
(ERK). Administration of agents that can increase the 
expression of Nrf2, such as dihydro-CDDO-trifluoromethyl 
amide (Dh404), can reduce nitrosative damage and 
phosphorylation of ERK, as well as prevent the disruption 
of insulin signalling pathways.(28)
 Flavonoids can increase the release of Nrf2 from its 
bond with Keap1, allowing activated Nrf2 to enter nucleus 
and to activate ARE that will in turn increase the production 
of antioxidative enzymes. Studies shows the ability of 
quercetin to reduce the risk of cardiomyopathy by lowering 
the oxidative stress in doxorubicin-induced rats.(29)
Conclusion
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